July 15, 2025

Table 3 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

View Full Paper

Ask AI

Bookmark

The study focuses on a first-in-class CDK2/4/6 inhibitor PF-06873600 for treating breast cancer.
The evaluation revealed dose-limiting toxicities (DLTs) by organ class in patients receiving this therapy.
Participants in the evaluable analysis set were monitored for adverse effects related to the treatment.
Findings may guide future research on combination therapies in breast cancer management.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase I/IIa study reports dose-limiting toxicities in breast cancer patients treated with a CDK2/4/6 inhibitor and endocrine therapy, highlighting its potential effects.

Cite This Study

Yap et al. (2025) studied this question.

synapsesocial.com/papers/689a02bce6551bb0af8cc6c5 https://doi.org/10.1158/1078-0432.29568353

View Full Paper

Ask AI

Bookmark

Implication

Phase I/IIa study reports dose-limiting toxicities in breast cancer patients treated with a CDK2/4/6 inhibitor and endocrine therapy, highlighting its potential effects.

Table 3 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

Key Points

Discussion

Implication

Cite This Study

Table 3 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider